摘要
目的 研究恩替卡韦联合六味瓦灵片对阿德福韦酯疗效欠佳的慢乙肝患者的疗效和安全性.方法 将2010年1月～2011年12月在沧州市传染病医院就诊的阿德福韦酯疗效欠佳的慢性乙型肝炎(Chronic hepatitis B,CHB)患者分为两组:恩替卡韦联合六味五灵片组(A组,66例)和单用阿德福韦酯组(B组,41例)完成12周和24周治疗时,检测HBV DNA水平、ALT水平、HBeAg与HBsAg的血清转化率及ADV耐药株.结果 治疗第12周时,HBV DNA>103 copies/ml的患者,A组占54.5%.B组占9.7%,P<0.001;第24周时,HBV DNA<300copies/ml的患者,A组占65.1%、B组占12.2%,P<0.001.从生化学应答和血清学转换率来看:治疗第12、24周时,ALT复常率、HBcAg转阴率和HBeAg 血清转换率A组均优于B组,P<0.001,差异有显著性.结论 恩替卡韦联合六味五灵片治疗阿德福韦酯疗效欠佳的慢乙肝患者,可在病毒学及生化学方面取得较好的疗效,且安全性好.
Objective To study the efficacy and safety on entacavir joint LiuWeiwuling tablets to treat the patients with chronic hepatitis B who were poor efficacy on the treatment of adefovir.Methods The patients with chronic hepatitis B accepted treatment from January 2010 to December 2011 in Cangzhou Infectious Disease Hospital were divided into two groups,group A and group B.66 cases in group A were treated with entacavir joint LiuWeiWulingtablets,and 41 cases in group B were teated with adefovir.After completing the treatment for 12 weeks and 24 weeks,the HBV DNA level,ALT levels,the seroconversion rate of HBsAg and HbeAg and the ADV resistant strains were detected.Results After being treated twelve weeks,the patients with HBV DNA>103 copies/ml occupied 54.5%in group A and 9.7%,in group B(P<0.001).The patients with HBV DNA< 300 copies/ml occupied 65.1%in group A and 12.2%,in group B(P<0.001) in 24 weeks.In view of biochemical response and serum conversion,the normal rate of ALT,the negative conversation rate of HbeAg,and the seroconversion rate of HBeAg in group A were better than those in group B(P< 0.001) in 12 and 24 weeks.Conclusion It could get better therapeutic effect on virological and biochemical aspects by using entacavir jointLiuWeiwuling tablets to treat the patients with chronic hepatitis B who had poor therapeutic effect on adefovi,and good safety.
出处
《热带病与寄生虫学》
2012年第4期209-211,共3页
Journal of Tropical Diseases and Parasitology
